share_log

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K：重大事件
美股SEC公告 ·  08/24 04:42
牛牛AI助理已提取核心訊息
Mangoceuticals, Inc., a Texas-based pharmaceutical company, has successfully completed the sale of an additional 500 shares of Series B Convertible Preferred Stock to an institutional accredited investor for $500,000 on August 22, 2024. This transaction is part of a partial fourth closing under a Securities Purchase Agreement (SPA) that was previously amended in April 2024. The shares were sold at a 10% discount to their stated value of $1,100 per share. The company's stockholders had approved this issuance at the Annual Meeting on June 17, 2024, in compliance with Nasdaq Listing Rule 5635(d). The rights and preferences of the Series B Preferred Stock have been detailed in prior reports filed with the SEC. The issuance was exempt from registration under the Securities Act of 1933, as it was not a public offering and the purchaser is an accredited investor. Additionally, on the same day, Mangoceuticals' Board of Directors approved an increase in the monthly car allowance for CEO Jacob Cohen from $1,500 to $2,500.
Mangoceuticals, Inc., a Texas-based pharmaceutical company, has successfully completed the sale of an additional 500 shares of Series B Convertible Preferred Stock to an institutional accredited investor for $500,000 on August 22, 2024. This transaction is part of a partial fourth closing under a Securities Purchase Agreement (SPA) that was previously amended in April 2024. The shares were sold at a 10% discount to their stated value of $1,100 per share. The company's stockholders had approved this issuance at the Annual Meeting on June 17, 2024, in compliance with Nasdaq Listing Rule 5635(d). The rights and preferences of the Series B Preferred Stock have been detailed in prior reports filed with the SEC. The issuance was exempt from registration under the Securities Act of 1933, as it was not a public offering and the purchaser is an accredited investor. Additionally, on the same day, Mangoceuticals' Board of Directors approved an increase in the monthly car allowance for CEO Jacob Cohen from $1,500 to $2,500.
總部位於德克薩斯州的藥品公司Mangoceuticals, Inc.已於2024年8月22日成功出售了500股B類可轉換優先股給一位機構認證投資者，交易金額爲50萬美元。該交易是根據此前於2024年4月修訂的證券購買協議（SPA）的第四次局部封閉的一部分。這些股票按照每股1100美元的票面價值折價10%出售。公司股東在2024年6月17日的年度會議上批准了這一發行，符合納斯達克上市規則5635(d)。B類優先股的權益和優先權已在之前提交給美國證券交易委員會的報告中詳細說明。此次發行豁免了1933年證券法的登記要求，因爲它不是公開發行，而且購買者是一位認證投資者。此外，同一天，Mangoceuticals的董事會還批准將CEO Jacob Cohen的每月汽車津貼從1500美元提高到2500美元。
總部位於德克薩斯州的藥品公司Mangoceuticals, Inc.已於2024年8月22日成功出售了500股B類可轉換優先股給一位機構認證投資者，交易金額爲50萬美元。該交易是根據此前於2024年4月修訂的證券購買協議（SPA）的第四次局部封閉的一部分。這些股票按照每股1100美元的票面價值折價10%出售。公司股東在2024年6月17日的年度會議上批准了這一發行，符合納斯達克上市規則5635(d)。B類優先股的權益和優先權已在之前提交給美國證券交易委員會的報告中詳細說明。此次發行豁免了1933年證券法的登記要求，因爲它不是公開發行，而且購買者是一位認證投資者。此外，同一天，Mangoceuticals的董事會還批准將CEO Jacob Cohen的每月汽車津貼從1500美元提高到2500美元。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。